ImmunityBio, Inc.
IBRX
$7.25
$0.081.12%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 140.64M | 112.98M | 81.92M | 56.09M | 30.66M |
| Total Other Revenue | 337.00K | 306.00K | 639.00K | 510.00K | 563.00K |
| Total Revenue | 140.98M | 113.29M | 82.56M | 56.60M | 31.22M |
| Cost of Revenue | 933.00K | 753.00K | 371.00K | 194.00K | 58.00K |
| Gross Profit | 140.04M | 112.54M | 82.18M | 56.41M | 31.16M |
| SG&A Expenses | 161.92M | 148.80M | 151.81M | 151.44M | 158.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 402.37M | 369.32M | 343.30M | 341.97M | 344.64M |
| Operating Income | -261.39M | -256.03M | -260.74M | -285.37M | -313.42M |
| Income Before Tax | -854.50M | -351.61M | -348.69M | -367.14M | -409.42M |
| Income Tax Expenses | 108.00K | -135.00K | 0.00 | 35.00K | -234.00K |
| Earnings from Continuing Operations | -854.60 | -351.47 | -348.69 | -367.17 | -409.18 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 69.00K | 74.00K | 77.00K | 79.00K | 80.00K |
| Net Income | -854.53M | -351.40M | -348.62M | -367.09M | -409.10M |
| EBIT | -261.39M | -256.03M | -260.74M | -285.37M | -313.42M |
| EBITDA | -245.41M | -240.60M | -244.95M | -269.07M | -296.59M |
| EPS Basic | -0.85 | -0.39 | -0.41 | -0.46 | -0.55 |
| Normalized Basic EPS | -0.53 | -0.24 | -0.25 | -0.29 | -0.34 |
| EPS Diluted | -0.85 | -0.39 | -0.42 | -0.49 | -0.59 |
| Normalized Diluted EPS | -0.53 | -0.24 | -0.25 | -0.29 | -0.34 |
| Average Basic Shares Outstanding | 3.85B | 3.68B | 3.42B | 3.17B | 2.97B |
| Average Diluted Shares Outstanding | 3.85B | 3.68B | 3.42B | 3.17B | 2.97B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |